The Alere NMP22® BladderChek® Test is a fast, easy to use and non-invasive test that aids in the diagnosis and monitoring of bladder cancer, in conjunction with standard diagnostic procedures. With results in 30 minutes at the point-of-care, results can be delivered to patients during the same office visit, allowing a rapid and cost-effective aid in the detection of bladder cancer in patients at risk.
BENEFITS
CE-marked and CLIA-waived.
FDA cleared in the US for professional point-of-care and prescription home use.
Ability to test patients at risk for bladder cancer.
Easy testing process, only requiring 4 drops of urine to run the test.
Fast results in 30 minutes, allowing consultation during the same visit.
An ideal adjunct marker to cystoscopy as found in one study:
99% NPV overall when combined with cystoscopy, the most effective diagnostic combination for ruling out bladder cancer.1,2